On February 11, 2022, it was determined that Dolca Thomas, M.D. would cease serving as the Company's Executive Vice President of Research & Development and Chief Medical Officer and separate from the Company effective as of February 25, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | 0.00% | -9.41% | +113.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+113.00% | 54.29M | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Equillium, Inc. Announces Cessation of Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer